Overview

* Corvus Q2 net loss widens to $8.0 mln from $4.3 mln a year ago

* Company raised $35.7 mln from stock warrants, boosting cash reserves to $74.4 mln

* Advancing soquelitinib in trials for atopic dermatitis and T cell lymphoma

Outlook

* Company to report data from Phase 1 trial extension cohort 4 in Q4 2025

* Phase 2 trial for soquelitinib in atopic dermatitis to start before year-end

* Angel Pharmaceuticals to initiate Phase 1b/2 trial in China for soquelitinib

* Enrollment continues in Phase 3 trial for PTCL and Phase 2 trial for ALPS

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.1

Q2 Net -$8 mln

Income

Q2 Basic -$0.1

EPS

Q2 $10.26

Operatin mln

g

Expenses

Q2 -$10.26

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc ( CRVS ) is $13.00, about 67.9% above its August 6 closing price of $4.17

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)